News
TLSI
3.590
-1.91%
-0.070
Press Release: TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call
Dow Jones · 4d ago
Weekly Report: what happened at TLSI last week (1012-1016)?
Weekly Report · 6d ago
Full Transcript: TriSalus Life Sciences Q2 2026 Earnings Call
Benzinga · 10/12 09:38
Weekly Report: what happened at TLSI last week (1005-1009)?
Weekly Report · 10/12 09:33
Weekly Report: what happened at TLSI last week (0928-1002)?
Weekly Report · 10/05 09:33
Two new option listings on October 1st
TipRanks · 10/01 12:36
H.C. Wainwright Keeps Their Buy Rating on TriSalus Life Sciences (TLSI)
TipRanks · 10/01 10:35
Weekly Report: what happened at TLSI last week (0921-0925)?
Weekly Report · 09/28 09:31
Crude Oil Gains 1%; Cintas Earnings Top Views
Benzinga · 09/23 18:08
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support
Benzinga · 09/23 17:26
Midday Fly By: McDonald’s lays out new strategy, General Mills reports Q1 beat
TipRanks · 09/23 16:00
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
Benzinga · 09/23 14:02
Analysts Conflicted on These Healthcare Names: TriSalus Life Sciences (TLSI) and Eli Lilly & Co (LLY)
TipRanks · 09/23 13:30
Microsoft To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga · 09/23 12:57
At a glance: stocks gapping up premarket
Seeking Alpha · 09/23 11:27
Market-Moving News for September 23rd
Benzinga · 09/23 11:21
Canaccord Genuity Sticks to Its Buy Rating for TriSalus Life Sciences (TLSI)
TipRanks · 09/23 11:16
TriSalus Life Sciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 09/23 10:53
TriSalus Life Sciences Price Target Raised to $12.00/Share From $11.00 by HC Wainwright & Co.
Dow Jones · 09/23 10:53
HC Wainwright & Co. Maintains Buy on TriSalus Life Sciences, Raises Price Target to $12
Benzinga · 09/23 10:43
More
Webull provides a variety of real-time TLSI stock news. You can receive the latest news about TriSalus Life Sciences Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TLSI
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. It is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technological applications. Its delivery method, Pressure-Enabled Drug Delivery (PEDD), modulates pressure and flow within blood vessels to improve intravascular therapeutic delivery into tumors, thereby increasing the likelihood of tumor response in comparison to conventional delivery technologies. Its on-market TriNav Infusion System using PEDD technology, is being used for interventional radiology procedures, commonly transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or in patients with liver metastases. TriNav is a device with a novel (PEDD) delivery method.